CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis

Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration–response relationship of rituximab in RA patients.

• Publication year

  2019

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2019-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.14102PMID 31454097PMCID PMC6955400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis

  2019cited by this paper
• Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

  2017cited by this paper
• Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

  2016cited by this paper
• Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab

  2015cited by this paper
• Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

  2015cited by this paper
• Influence of Fc&ggr;RIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients

  2014cited by this paper
• Direct and Indirect Rituximab‐Induced T Cell Depletion: Comment on the Article by Mélet et al

  2014cited by this paper
• Reply

  2014cited by this paper
• Towards an individualised target concentration of adalimumab in rheumatoid arthritis

  2014cited by this paper
• Is There an Interactive Effect of Immunoglobulin Levels and CD4+ Cell Counts During Rituximab Treatment? Comment on the Article by Mélet et al

  2014cited by this paper
• Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.

  2013cited by this paper
• Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.

  2013cited by this paper
• Human memory T cells: generation, compartmentalization and homeostasis

  2013cited by this paper
• CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.

  2013cited by this paper
• Quantifying T lymphocyte turnover.

  2013cited by this paper
• Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

  2012cited by this paper
• Distinct roles of dendritic and B cells in the activation of naive CD4+ T cells.

  2012cited by this paper
• Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.

  2011cited by this paper
• Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.

  2011cited by this paper
• Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.

  2011cited by this paper
• Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.

  2011cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

  2009cited by this paper
• Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

  2008cited by this paper
• Alterations of the CD4+, CD8+ T Cell Subsets, Interleukins-1β, IL-10, IL-17, Tumor Necrosis Factor-α and Soluble Intercellular Adhesion Molecule-1 in Rheumatoid Arthritis and Osteoarthritis: Preliminary Observations

  2008cited by this paper
• Rituximab (MabThera) therapy and safety management. Clinical tool guide.

  2008cited by this paper
• Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.

  2008cited by this paper
• Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.

  2008cited by this paper
• New therapies for treatment of rheumatoid arthritis.

  2007cited by this paper
• Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response

  2007cited by this paper
• Evaluation of a peptide ELISA for the detection of rituximab in serum.

  2007cited by this paper
• Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo

  2006cited by this paper
• Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

  2006cited by this paper
• Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo.

  2006cited by this paper
• Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action

  2005cited by this paper
• Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial

  2005cited by this paper
• T Cell Activation in Rheumatoid Synovium Is B Cell Dependent1

  2001cited by this paper
• Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans

  1999cited by this paper
• Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

  1998cited by this paper
• Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir

  1997cited by this paper
• CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity.

  1996cited by this paper
• CD4 CD7 CD28 T Cells Are Expanded in Rheumatoid Arthritis and Are Characterized by Autoreactivity

  1996cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis.

  1994cited by this paper
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994cited by this paper
• The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.

  1987cited by this paper

• Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease

  2025cites this paper
• Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics

  2025cites this paper
• Medication-related osteonecrosis of the jaw (MRONJ) systemic review: mevalonate pathway mechanisms explored.

  2024cites this paper
• Identification of a novel cuproptosis‐related gene signature for rheumatoid arthritis—A prospective study

  2023cites this paper
• Impact and Tolerance of Immunosuppressive Treatments in Patients Living with HIV with Inflammatory or Autoimmune Diseases

  2022cites this paper
• Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study

  2022cites this paper
• Long-Term Follow-Up and Immunomonitoring of Relapsing Type 1 Autoimmune Pancreatitis Treated With Rituximab

  2022cites this paper
• The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

  2021cites this paper
• Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis

  2021cites this paper
• Role of B Cells in Multiple Sclerosis and Related Disorders

  2020cites this paper
• The Influence of Different Disease States on Rituximab Pharmacokinetics.

  2020cites this paper
• Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications

  2020cites this paper
• Effects of rituximab therapy on B cell differentiation and depletion

  2020cites this paper
• Inclusion‐body myositis and primary Sjögren syndrome: mechanisms for shared etiologies

  2020cites this paper
• CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis

  2019cites this paper